Skip to main content

Day: March 17, 2021

Sogeclair: résultats annuels 2020

Blagnac, France, le 17 mars 2021-17h35,Montréal, CanadaRESULTATS ANNUELS 2020Chiffre d’affaires consolidé : 123,1 M€ soit -33,5% (dont international : -38,0%)EBITDA(1) = 6,5 M€Provisions et charges liées à la Covid-19 = 14,4 M€SOGECLAIR, concepteur et producteur de solutions innovantes à forte valeur ajoutée pour la mobilité, annonce aujourd’hui ses résultats pour l’exercice clos le 31 décembre 2020.Dans un contexte de marché marqué par la pandémie de la Covid-19, SOGECLAIR s’est montré réactif :Les mesures d’adaptation ont été engagées dès le 1er semestre 2020 (simplification juridique, redressement de la filiale allemande, adaptation des effectifs).En parallèle, des succès commerciaux ont pu être réalisés avec des gains de contrats pluriannuels notamment pour la division Aerospace.Au total, les décisions engagées dès le 1er semestre...

Continue reading

Bright Minds Biosciences Announces Closing of $25.9 Million Unit Offering

THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT AUTHORIZED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES.VANCOUVER, British Columbia, March 17, 2021 (GLOBE NEWSWIRE) — Bright Minds Biosciences Inc. (CSE:DRUG) (“Bright Minds” or the “Company”) is pleased to announce that it has closed its previously announced underwritten public offering (the “Offering”) of units (the “Units”) of the Company. Eight Capital acted as lead underwriter and sole bookrunner in connection with the Offering on behalf of a syndicate of underwriters including Stifel GMP, Beacon Securities Limited and Haywood Securities Inc. (collectively, the “Underwriters”).Pursuant to the terms of the Offering, the Company issued 3,419,883 Units, including 116,883 Units issued pursuant to the exercise...

Continue reading

Todos Medical Provides Corporate Update

PCR COVID lab sales strengthening as the US prepares to implement serial COVID testing programs to further re-open the economyScaling molecular lab business by deepening COVID offering and preparing to expand into complementary testing verticals aligned with Todos’ cancer and Alzheimer’s IP TestingNovel 3CL protease biomarker theragnostic offering being positioned for actionable COVID PCR reflex testing and complementary inhibitor solutions potentialStrengthened balance sheet and catalysts positioning Todos for national exchange listingNEW YORK, NY, REHOVAT, ISRAEL, March 17, 2021 (GLOBE NEWSWIRE) — via NewMediaWire — Todos Medical, Ltd. (OTCQB: TOMDF), an in vitro diagnostics company focused on distributing comprehensive solutions for COVID-19 screening, diagnosis and immune support, as well as developing blood tests for...

Continue reading

Gofore Plc: Gofore Plc’s directed share issue for the transfer of shares in employee share savings plan

GOFORE PLC STOCK EXCHANGE RELEASE 17 MARCH 2021 AT 18.05 EETGofore Plc’s directed share issue for the transfer of shares in employee share savings planAs a part of the Gofore Group’s employee share savings plan, CrewShare (“plan”), Gofore Plc’s Board of Directors has resolved today to issue a total of 15,304 new shares. The new shares issued account for matching shares paid on the basis of the savings period 2018 (CrewShare 2018) and savings shares acquired with savings from the savings period 2020-2021 (CrewShare 2020). More detailed information about the plan and its savings periods were published in the company announcements on 28 September 2018 and 13 February 2020. The share issue is based on the authorisation by the Annual General Meeting held on 29 April 2020.A total of 2,454 new shares are issued without consideration to the plan...

Continue reading

Gofore Oyj: Gofore Oyj:n suunnattu osakeanti henkilöstön osakesäästöohjelman perusteella

GOFORE OYJ PÖRSSITIEDOTE 17.3.2021 KLO 18.05Gofore Oyj:n hallitus on tänään päättänyt yhteensä 15 304 uuden osakkeen liikkeelle laskemisesta osana konsernin henkilöstön CrewShare -osakesäästöohjelmaa (“ohjelma”). Uudet osakkeet ovat osakesäästöohjelman säästökauden 2018 (CrewShare 2018) perusteella palkkiona maksettavia lisäosakkeita ja säästökaudelta 2020-2021 (CrewShare 2020) kertyneillä säästöillä hankittavia säästöosakkeita. Ohjelmasta ja sen säästökausista on tiedotettu tarkemmin 28.9.2018 ja 13.2.2020 julkaistuissa yhtiötiedotteissa.Osakeanti perustuu varsinaisen yhtiökokouksen 29.4.2020 antamaan valtuutukseen. CrewShare 2018 -ohjelmassa luovutetaan vastikkeetta yhteensä 2 454 uutta osaketta ohjelman ehtojen mukaisesti lisäosakkeina säästökaudella 2018 hankittuja säästöosakkeita vastaan.CrewShare 2020-ohjelman perusteella...

Continue reading

Uponor revises its guidance for 2021

Uponor Corporation     Inside information     17 March 2021     18:00 EETUponor revises its guidance for 2021Uponor communicated in its financial statements bulletin on 11 February that the company has had a strong start for the year 2021. “Despite of the general economic uncertainties generated by the COVID-19 pandemic, the demand in Uponor’s key markets in Europe and North America has stayed on a good level. The activity in the North American residential building segment, in particular, continues on a high level. In addition, as commented in February, there were already some signs of increases in our input costs and we have seen this trend strengthening since then. We will mitigate this development with price increases, which will also contribute to the net sales. Therefore we are changing our guidance in respect of the net sales and...

Continue reading

Uponor päivittää vuoden 2021 ohjeistustaan

Uponor Oyj     Sisäpiiritieto           17.3.2021     18.00Uponor päivittää vuoden 2021 ohjeistustaanUponor kertoi tilinpäätöstiedotteessaan 11.2., että yhtiön vuosi 2021 on alkanut vahvasti. ”Huolimatta COVID-19-pandemian aiheuttamasta yleisestä taloudellisesta epävarmuudesta, kysyntä Uponorin päämarkkinoilla Euroopassa ja Pohjois-Amerikassa on pysynyt hyvällä tasolla. Erityisesti aktiivisuus Pohjois-Amerikan asuntomarkkinoilla jatkuu korkeana. Lisäksi, kuten kerroimme helmikuussa, osassa hankinnan ja valmistuksen kuluistamme on näkyvissä nousua, ja tämä trendi on vain vahvistunut. Hillitsemme tätä kehitystä hinnankorotuksilla, mikä osaltaan vaikuttaa myös liikevaihtoomme. Siksi muutamme ohjeistustamme liikevaihdon osalta ja säilytämme aiemman ohjeistuksen vertailukelpoisen liikevoiton osalta”, kertoo Uponorin toimitusjohtaja Jyri Luomakoski.Uusi...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.